Sensyne Health PLC (LON:SENS) said its SYNE-COVTM machine learning algorithm for COVID-19 risk prediction has received regulatory approval for use in the UK.
Developed in collaboration with the Chelsea & Westminster Hospitals NHS Foundation Trust, it is the first algorithm developed from the SENSE clinical and operational engine to achieve sign-off.
It analyses over 60 variables in the patient electronic health record to generate a prediction of the likelihood of a COVID-19 positive patient developing severe disease, requiring ventilation or admission to intensive care.
Sensyne said it will market the algorithm to NHS trusts to help them with coronavirus preparedness in “good time” for the 2021/22 winter season.
"This is the first Sensyne Clinical AI algorithm to achieve regulatory approval that has been developed using our SENSE clinical AI platform,” said chief executive Paul Drayson.
“The SENSE engine is expected to be able to generate clinical algorithms across a range of medical conditions that will provide real-time clinical decision-making support. Achieving the first regulatory approval is an important milestone for the Company and we look forward to being able to roll SYNE-COV out to the NHS."